Researchers at the ADA reported that Liraglutide reverses prediabetes indices in most obese patients with existing prediabetes …Full Story
Nick Finer, MD, University College London, United Kingdom, reported the results of change in prediabetes status from a double-blind, placebo-controlled trial in obese nondiabetic patients with liraglutide doses up to 3.0 mg.
Dr. Finer said that, "The prevalence of obesity has increased 3-fold in the last 2 decades” and that, "obesity increases the risk for development of Type 2 diabetes and is usually preceded by prediabetes."
The study included 564 patients with a body mass index (BMI) between 30 and 40 kg/m2 who were randomized to once-daily subcutaneous liraglutide (1 of 4 doses), placebo or oral orlistat. The liraglutide dose was increased by weekly increments of 0.6 mg. Of the patients, 75 had prediabetes.
All subjects were prescribed a reduced calorie diet and encouraged to increase physical activity by the use of pedometers.
In the intent-to-treat population (561 patients) with last observation carried forward, estimated mean placebo-subtracted weight loss from randomisation was 2.1 kg (for liraglutide 1.2 mg) to 4.4 kg (for liraglutide 3.0 mg).
Overall, the prediabetes incidence was reduced by roughly 90% with liraglutide 1.8 to 3.0 mg.
In a post hoc analysis, liraglutide-treated patients had significantly higher odds of having normal glucose tolerance at week 20 compared with placebo or orlistat (P < .01 for all orlistat doses).
The most common adverse events with liraglutide were nausea and vomiting.
Overall, the results demonstrated that liraglutide treatment decreases the incidence of prediabetes and reverses existing prediabetes in obese patients over 20 weeks, Dr. Finer said.
[Presentation title: Liraglutide, a Once-Daily Human GLP-1 Analog Reverses Indices of Prediabetes in Obese Subjects: A Randomized, Placebo-Controlled 20-Week Trial. Abstract 1729-P]
DID YOU KNOW: